Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosilate for emergence delirium after elective gastrointestinal cancer surgery
ChiCTR2100046788Phase 4Recruiting
- Sponsor
- First People's Hospital of Lianyungang City
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, midazolam and propofol in Emergence agitation (EA) (3 arms), sponsored by First People's Hospital of Lianyungang City. Primary endpoints: Incidence of emergence delirium and Regional cerebral oximetry. Started Jun 2021; status: recruiting.
02
Drugs
remimazolammidazolampropofol
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on ChiCTR2100046788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046788.